Acrivon ipo pricing
WebNov 15, 2024 · Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") ACRV, a clinical stage biopharmaceutical company developing precision oncology medicines that WebApr 12, 2024 · According to analysts' consensus price target of $21.00, Acrivon Therapeutics has a forecasted upside of 138.9% from its current price of $8.79. Amount of Analyst Coverage Acrivon Therapeutics has received no research coverage in the past 90 days. See Top Rated MarketRank™ Stocks Here About Acrivon Therapeutics …
Acrivon ipo pricing
Did you know?
WebAcrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline Acrivon Therapeutics 06. 29. 2024 Acrivon Therapeutics Launches to Advance Clinical Oncology Pipeline Leveraging its Groundbreaking Precision Proteomics Platform Events & … WebNov 15, 2024 · Acrivon Therapeutics, a Phase 2 biotech developing proteomics-based precision oncology therapies, raised $94 million by offering 7.6 million shares at $12.50, …
WebAcrivon Therapeutics has raised a total of $115.5M in funding over 2 rounds. Their latest funding was raised on Nov 11, 2024 from a Series B round. Acrivon Therapeutics is … WebNov 8, 2024 · Precision oncology drug developer Acrivon Therapeutics (ACRV) has updated terms for a proposed $100M initial public offering, which would make it one of …
Web9 rows · Nov 14, 2024 · Acrivon’s shares are expected to begin trading on the Nasdaq Global Market on November 15, 2024 ... WebAcrivon Therapeutics, Inc. (ACRV) is planning to raise $100 million in an initial public offering (IPO) on Thursday, November 10th, IPO Scoop reports. The company plans to issue 5,900,000 shares at a price of $16.00-$18.00 per share. The company has a market cap of $319.8 million. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as […]
WebNov 15, 2024 · After delaying its offering by a few days, the company sold 7,550,000 shares at $12.50 apiece. It also agreed to sell another 400,000 shares at the IPO price to its top …
WebAbout. We are a clinical stage oncology company leveraging our unique precision medicine platform, called Acrivon Predictive Precision Proteomics (AP3), for development of our drug pipeline. AP3 is used to generate proprietary OncoSignature® companion diagnostics to identify the patients who will benefit from our medicines. The name Acrivon ... delaney brey facebookWeb27 rows · Business: ( Note: Acrivon Therapeutics priced its IPO on Monday night, Nov. 14, 2024, at $12.50 ... fentanyl analog potencyWebAcrivon Therapeutics, Inc. (ACRV) Stock Price, News, Quote & History - Yahoo Finance U.S. markets closed Acrivon Therapeutics, Inc. (ACRV) NasdaqGM - NasdaqGM Real … delaney boot propetWebNov 9, 2024 · Acrivon announced last Thursday that it would be offering 5.9 million shares at a range between $16.00 to $18.00. The IPO is due to price on Wednesday night, November 9, before floating on... delaney book for teachersWebNov 7, 2024 · A Watertown startup testing a drug licensed from Eli Lilly & Co. in midstage trials has filed for a $100 million IPO. Acrivon Therapeutics Inc. is scheduled to pull off the deal this week ... delaney browne appointmentsWebNov 15, 2024 · This compares to a net loss of $4.3 million and $16.2 million, respectively, for the same periods in 2024. As of December 31, 2024, the company had cash, cash equivalents and marketable securities of $169.6 million, which is expected to fund operations at least into the fourth quarter of 2024. Recommended For You Mar 20, 2024 fentanyl analogs listWebNov 6, 2024 · recision oncology biotech Acrivon Therapeutics (ACRV) plans to raise $100 million at a $351 million market cap. The company’s lead candidate is in a potentially registrational Phase 2 trial across multiple tumor types, focusing on platinum-resistant ovarian, endometrial, and bladder cancers, with initial readouts expected in the 2H23. delaney brown cpp